trending Market Intelligence /marketintelligence/en/news-insights/trending/ccLGKWNe5h55S2NU9FlTBw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Stealth BioTherapeutics stock drops 66% on failed rare disease trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Stealth BioTherapeutics stock drops 66% on failed rare disease trial

Stealth BioTherapeutics Corp.'s experimental therapy elamipretide for a genetic disorder affecting the skeletal muscles failed to improve patients' walking ability and fatigue in a late-stage trial.

Newton, Mass.-based Stealth's stock dropped by 66.1% to $4.72 as of 9:55 a.m. ET on Dec. 20.

The biotechnology company will assess operational resources following these results and provide next steps in January 2020, according to a Dec. 20 press release.

Elamipretide was evaluated in a 32-week phase 3 trial called MMPOWER-3 for primary mitochondrial myopathy, a rare disease characterized by mutations in the mitochondria that affect the skeletal muscle, leading to insufficient energy in the cells. Primary mitochondrial myopathy can also cause muscle fatigue, muscle pain and muscle wasting.

While elamipretide was well-tolerated among the 218 enrolled patients, the drug candidate failed to improve how far patients could walk in a six-minute walk test and fatigue and muscle weakness symptoms.

The company is also testing elamipretide for another rare mitochondrial disorder called Barth syndrome. Stealth intends to meet with the U.S. Food and Drug Administration in early 2020 to determine next steps, as elamipretide has been shown to improve patients' condition in clinical trials for Barth syndrome.